Showing 731-740 of 10588 results for "".
Insights for Postmenopausal Osteoporosis Patients at Very High Risk of Fracture
https://reachmd.com/programs/medical-industry-feature/postmenopausal-osteoporosis-high-fracture-risk/27132/Starting with the presence of a prior fracture, advancing age, and bone mineral density, there are numerous factors that increase the risk of fracture in postmenopausal women.1 But despite these common predictors, treatment rates of osteoporosis in postmenopausal women have consistently remained lowClosing the Gap to Care: Assessing CAD and Improving Patient Outcomes with Revascularization
https://reachmd.com/programs/cme/closing-the-gap-to-care-assessing-cad-and-improving-patient-outcomes-with-revascularization/14855/Are we really doing our best to assess CAD in our patients? Experts discuss ways to close gaps in care and improve patient outcomes.Frontline Insights: Emerging Therapeutic Strategies in HNSCC
https://reachmd.com/programs/cme/Frontline-Insights-Emerging-Therapeutic-Strategies-in-HNSCC/49223/Review emerging therapeutic strategies in HNSCC across disease states and learn to compare safety profile to improve AE recognition, prevention, and management.Case-Based Management of AAV
https://reachmd.com/programs/cme/case-based-management-of-aav/14963/Given the unmet needs in AAV treatment with glucocorticoids, there may be a role for complement receptor inhibition. Hear more from our experts!Macular Leakage: Indicator of Vascular Stability
https://reachmd.com/programs/cme/Macular-Leakage-Indicator-of-Vascular-Stability-2510/33105/Hear about new biomarkers for assessing retinal disease activity and their clinical significance when using of second-generation agents.Unresectable HCC: An Emerging Era of Combination Therapy – A Clinical Convergence®
https://reachmd.com/programs/cme/unresectable-hcc-an-emerging-era-of-combination-therapy-a-clinical-convergence/12029/Don’t miss this opportunity to learn more about combination strategies, with practical guidance on their integration into clinical practice.A Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway
https://reachmd.com/programs/cme/a-novel-therapeutic-approach-in-myeloid-malignancies-targeting-the-neddylation-pathway/11694/Learn about emerging NEDD8-activating enzyme inhibitors in myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).Integrating Patient Perspectives in Dermatologic Care
https://reachmd.com/programs/dermconsult/patient-perspectives-dermatologic-care/37245/Clinicians are trying to align care with individual patient needs for the approximately eight million American adults and over 125 million people worldwide living with psoriasis.1 In the ENCOMPASS study’s US arm, researchers examined treatment experiences, satisfaction, and perceptions of therapiesAre You On Top of Pediatric Atopic Dermatitis? Expert Guidance for Leveraging the Latest Advances in Systemic Therapy
https://reachmd.com/programs/cme/are-you-on-top-of-pediatric-atopic-dermatitis-expert-guidance-for-leveraging-the-latest-advances-in-systemic-therapy/54260/On-demand webcast of expert faculty presentation on the disease burden of pediatric atopic dermatitis and strategies for helping patients achieve disease control with systemic therapy.Test Your Skills and Learn From Experts on Best Practice in Diagnosis and Management of Systemic Mastocytosis
https://reachmd.com/programs/cme/test-your-skills-and-learn-from-experts-on-best-practice-in-diagnosis-and-management-of-systemic-mastocytosis/54694/On-demand webcast featuring expert-informed best practices for diagnosing and managing patients with systemic mastocytosis (SM) as well as the latest data on new and emerging SM therapies.